Drug Master File (DMF): Regulatory Framework, Global Perspectives, and Challenges

Authors:

Gumba Lollen

Abstract

Drug Master Files (DMFs) play an important role in the pharmaceutical industry by providing confidential information about the manufacturing, processing, packaging, and quality control of drug substances and drug products to regulatory authorities. They help pharmaceutical companies protect proprietary information while supporting the review and approval of medicines. With the increasing globalization of the pharmaceutical market, DMFs have become a key component in ensuring product quality, safety, and regulatory compliance. However, differences in regulatory requirements across countries, complex documentation procedures, frequent regulatory updates, and growing expectations for electronic submissions have created significant challenges for manufacturers and regulatory professionals.

The objective of this review is to examine the regulatory framework governing Drug Master Files in major pharmaceutical markets, including the United States, Europe, Japan, Canada, and India, and to identify the major challenges associated with DMF preparation, submission, and maintenance. This review was conducted through an analysis of published scientific literature, regulatory guidelines, and official documents obtained from databases such as PubMed, Scopus, Google Scholar, and regulatory agency websites.

The review highlights the importance of DMFs in facilitating drug approval processes and maintaining regulatory compliance. It also identifies key challenges such as variations in global regulatory requirements, documentation complexity, data integrity concerns, electronic submission requirements, and confidentiality issues. Furthermore, the review discusses recent developments in digital regulatory systems, electronic Drug Master Files (eDMFs), and efforts toward international regulatory harmonization.

Overall, Drug Master Files remain an essential regulatory tool for ensuring the quality and safety of pharmaceutical products. Greater harmonization of global regulatory requirements, improved digital infrastructure, and enhanced regulatory guidance can help reduce submission challenges and improve the efficiency of regulatory review processes. The findings of this review may assist regulatory authorities, pharmaceutical manufacturers, and researchers in understanding current DMF practices and identifying opportunities for future improvement.

Keywords: Drug Master File, DMF, Regulatory Affairs, Pharmaceutical Regulation, eDMF, Drug Approval, Regulatory Compliance, Quality Assurance, Global Harmonization.